Epigenetic changes in diabetes

Clinical Genetics

Volumn 84, Issue 1, 2013, Pages 1-10

  Keating, St ^a   El Osta, A ^a,b,c,d  

^a Epigenetics in Human Health and Disease Laboratory   (Australia)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d MONASH UNIVERSITY   (Australia)

Author keywords

Chromatin; Complications; Diabetes; Epigenetic; Histones; Metabolic memory; Methylation

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALLOXAN; CPG OLIGODEOXYNUCLEOTIDE; CYTOSINE; DNA; GLUCOKINASE; GLUCOSE; HEMOGLOBIN A1C; HISTONE; HISTONE ACETYLTRANSFERASE; HISTONE H2A; HISTONE H2B; HISTONE H3; HISTONE H4; INSULIN; MANGANESE SUPEROXIDE DISMUTASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; POLYOL; PROTEIN KINASE C; PYRUVATE KINASE; REACTIVE OXYGEN METABOLITE; SOMATOMEDIN C; STAT3 PROTEIN; STREPTOZOCIN; TRANSCRIPTION FACTOR PDX 1; TRANSCRIPTION FACTOR RELA; UNCOUPLING PROTEIN 1;

ALLOXAN DIABETES MELLITUS; BLOOD SAMPLING; CHROMATIN; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DNA DAMAGE; DNA METHYLATION; DNA REPLICATION; DRUG SUBSTITUTION; EPIDEMIOLOGICAL DATA; EPIGENETICS; GENE CONTROL; GENE EXPRESSION; GENE OVEREXPRESSION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HISTONE MODIFICATION; HUMAN; HUMAN GENOME; HYPERGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MEMORY; METABOLIC DISORDER; MOLECULAR DYNAMICS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; STREPTOZOCIN DIABETES;

CHROMATIN; DIABETES COMPLICATIONS; DIABETES MELLITUS; DISEASE PROGRESSION; DNA METHYLATION; EPIGENESIS, GENETIC; GENE-ENVIRONMENT INTERACTION; HISTONES; HUMANS; PHENOTYPE; PROTEIN PROCESSING, POST-TRANSLATIONAL; TRANSCRIPTION, GENETIC;

ANIMALIA;

EID: 84879796488     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/cge.12121     Document Type: Review

References (132)

1. Venter JC, Adams MD, Myers EW et al. The sequence of the human genome. Science 2001: 291: 1304-1351.
2. Lander ES, Linton LM, Birren B et al. Initial sequencing and analysis of the human genome. Nature 2001: 409: 860-921.
3. Jenuwein T, Allis CD. Translating the histone code. Science 2001: 293: 1074-1080.
4. Ogryzko VV. Erwin Schroedinger, Francis Crick and epigenetic stability. Biol Direct 2008: 3: 15.
5. Bernstein BE, Meissner A, Lander ES. The mammalian epigenome. Cell 2007: 128: 669-681.
6. Butler JE, Kadonaga JT. The RNA polymerase II core promoter: a key component in the regulation of gene expression. Genes Dev 2002: 16: 2583-2592.
7. Svejstrup JQ. The RNA polymerase II transcription cycle: cycling through chromatin. Biochim Biophys Acta 2004: 1677: 64-73.
8. Pennisi E. Behind the scenes of gene expression. Science 2001: 293: 1064-1067.
9. Jones PA, Takai D. The role of DNA methylation in mammalian epigenetics. Science 2001: 293: 1068-1070.
10. Feil R, Fraga MF. Epigenetics and the environment: emerging patterns and implications. Nat Rev Genet 2012: 13: 97-109.
11. Rhee I, Bachman KE, Park BH et al. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 2002: 416: 552-556.
12. Laird PW, Jaenisch R. The role of DNA methylation in cancer genetic and epigenetics. Annu Rev Genet 1996: 30: 441-464.
13. Herman JG, Baylin SB. Promoter-region hypermethylation and gene silencing in human cancer. Curr Top Microbiol Immunol 2000: 249: 35-54.
14. Kelly TK, De Carvalho DD, Jones PA. Epigenetic modifications as therapeutic targets. Nat Biotechnol 2010: 28: 1069-1078.
15. Cooper ME, El-Osta A. Epigenetics: mechanisms and implications for diabetic complications. Circ Res 2010: 107: 1403-1413.
16. Meigs JB, Cupples LA, Wilson PW. Parental transmission of type 2 diabetes: the Framingham offspring study. Diabetes 2000: 49: 2201-2207.
17. Poulsen P, Kyvik KO, Vaag A, Beck-Nielsen H. Heritability of type II (non-insulin-dependent) diabetes mellitus and abnormal glucose tolerance-a population-based twin study. Diabetologia 1999: 42: 139-145.
18. Drong AW, Lindgren CM, McCarthy MI. The genetic and epigenetic basis of type 2 diabetes and obesity. Clin Pharmacol Ther 2012: 92: 707-715.
19. Hales CN, Barker DJ. Type 2 (non-insulin-dependent) diabetes mellitus: the thrifty phenotype hypothesis. Diabetologia 1992: 35: 595-601.
20. Pettitt DJ, Aleck KA, Baird HR, Carraher MJ, Bennett PH, Knowler WC. Congenital susceptibility to NIDDM. Role of intrauterine environment. Diabetes 1988: 37: 622-628.
21. Pettitt DJ, Baird HR, Aleck KA, Bennett PH, Knowler WC. Excessive obesity in offspring of Pima Indian women with diabetes during pregnancy. N Engl J Med 1983: 308: 242-245.
22. Pirola L, Balcerczyk A, Okabe J, El-Osta A. Epigenetic phenomena linked to diabetic complications. Nat Rev Endocrinol 2010: 6: 665-675.
23. King GL, Brownlee M. The cellular and molecular mechanisms of diabetic complications. Endocrinol Metab Clin North Am 1996: 25: 255-270.
24. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005: 54: 1615-1625.
25. Nishikawa T, Edelstein D, Brownlee M. The missing link: a single unifying mechanism for diabetic complications. Kidney Int Suppl 2000: 77: S26-30.
26. Kowluru RA, Kowluru V, Xiong Y, Ho YS. Overexpression of mitochondrial superoxide dismutase in mice protects the retina from diabetes-induced oxidative stress. Free Radic Biol Med 2006: 41: 1191-1196.
27. Shen X, Zheng S, Metreveli NS, Epstein PN. Protection of cardiac mitochondria by overexpression of MnSOD reduces diabetic cardiomyopathy. Diabetes 2006: 55: 798-805.
28. Zhang Y, Wada J, Hashimoto I et al. Therapeutic approach for diabetic nephropathy using gene delivery of translocase of inner mitochondrial membrane 44 by reducing mitochondrial superoxide production. J Am Soc Nephrol 2006: 17: 1090-1101.
29. Engerman RL, Kern TS. Progression of incipient diabetic retinopathy during good glycemic control. Diabetes 1987: 36: 808-812.
30. Kowluru RA. Effect of reinstitution of good glycemic control on retinal oxidative stress and nitrative stress in diabetic rats. Diabetes 2003: 52: 818-823.
31. Hammes HP, Klinzing I, Wiegand S, Bretzel RG, Cohen AM, Federlin K. Islet transplantation inhibits diabetic retinopathy in the sucrose-fed diabetic Cohen rat. Invest Ophthalmol Vis Sci 1993: 34: 2092-2096.
32. El-Osta A, Brasacchio D, Yao D et al. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. The Journal of experimental medicine 2008: 205: 2409-2417.
33. Roy S, Sala R, Cagliero E, Lorenzi M. Overexpression of fibronectin induced by diabetes or high glucose: phenomenon with a memory. Proc Natl Acad Sci USA 1990: 87: 404-408.
34. The Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. The DCCT Research Group. Diabetes 1986: 35: 530-545.
35. The Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003: 290: 2159-2167.
36. Cleary PA, Orchard TJ, Genuth S et al. The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes 2006: 55: 3556-3565.
37. Nathan DM, Lachin J, Cleary P et al. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 2003: 348: 2294-2303.
38. Nathan DM, Cleary PA, Backlund JY et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005: 353: 2643-2653.
39. Prospective UK. Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia 1991: 34: 877-890.
40. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008: 359: 1577-1589.
41. Kouzarides T. Chromatin modifications and their function. Cell 2007: 128: 693-705.
42. Kornberg RD. Chromatin structure: a repeating unit of histones and DNA. Science 1974: 184: 868-871.
43. Kornberg RD, Thomas JO. Chromatin structure; oligomers of the histones. Science 1974: 184: 865-868.
44. Luger K, Mader AW, Richmond RK, Sargent DF, Richmond TJ. Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 1997: 389: 251-260.
45. Chodaparambil JV, Edayathumangalam RS, Bao Y, Park YJ, Luger K. Nucleosome structure and function. Ernst Schering Res Found Workshop 2006: 57: 29-46.
46. Kornberg RD, Lorch Y. Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome. Cell 1999: 98: 285-294.
47. Hayes JJ, Hansen JC. Nucleosomes and the chromatin fiber. Curr Opin Genet Dev 2001: 11: 124-129.
48. Olins AL, Carlson RD, Olins DE. Visualization of chromatin substructure: upsilon bodies. J Cell Biol 1975: 64: 528-537.
49. Oudet P, Gross-Bellard M, Chambon P. Electron microscopic and biochemical evidence that chromatin structure is a repeating unit. Cell 1975: 4: 281-300.
50. Locklear L Jr, Ridsdale JA, Bazett-Jones DP, Davie JR. Ultrastructure of transcriptionally competent chromatin. Nucleic Acids Res 1990: 18: 7015-7024.
51. Bannister AJ, Kouzarides T. Regulation of chromatin by histone modifications. Cell Res 2011: 21: 381-395.
52. Roh TY, Cuddapah S, Zhao K. Active chromatin domains are defined by acetylation islands revealed by genome-wide mapping. Genes Dev 2005: 19: 542-552.
53. Roh TY, Wei G, Farrell CM, Zhao K. Genome-wide prediction of conserved and nonconserved enhancers by histone acetylation patterns. Genome Res 2007: 17: 74-81.
54. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 2003: 370: 737-749.
55. Wade PA, Wolffe AP. Histone acetyltransferases in control. Curr Biol 1997: 7: R82-R84.
56. Zhang Y, Reinberg D. Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. Genes Dev 2001: 15: 2343-2360.
57. Roth SY, Denu JM, Allis CD. Histone acetyltransferases. Annu Rev Biochem 2001: 70: 81-120.
58. Martin C, Zhang Y. The diverse functions of histone lysine methylation. Nat Rev Mol Cell Biol 2005: 6: 838-849.
59. Havas K, Whitehouse I, Owen-Hughes T. ATP-dependent chromatin remodeling activities. Cell Mol Life Sci 2001: 58: 673-682.
60. Varga-Weisz P. ATP-dependent chromatin remodeling factors: nucleosome shufflers with many missions. Oncogene 2001: 20: 3076-3085.
61. Hargreaves DC, Crabtree GR. ATP-dependent chromatin remodeling: genetics, genomics and mechanisms. Cell Res 2011: 21: 396-420.
62. Dai Z, Dai X, Xiang Q et al. Genome-wide analysis of interactions between ATP-dependent chromatin remodeling and histone modifications. BMC Genomics 2009: 10: 304.
63. Chatterjee N, Sinha D, Lemma-Dechassa M, Tan S, Shogren-Knaak MA, Bartholomew B. Histone H3 tail acetylation modulates ATP-dependent remodeling through multiple mechanisms. Nucleic Acids Res 2011: 39: 8378-8391.
64. Couture JF, Trievel RC. Histone-modifying enzymes: encrypting an enigmatic epigenetic code. Curr Opin Struct Biol 2006: 16: 753-760.
65. Fischle W, Wang Y, Allis CD. Histone and chromatin cross-talk. Curr Opin Cell Biol 2003: 15: 172-183.
66. Strahl BD, Allis CD. The language of covalent histone modifications. Nature 2000: 403: 41-45.
67. Turner BM. Histone acetylation and an epigenetic code. Bioessays 2000: 22: 836-845.
68. Shanmugam N, Reddy MA, Guha M, Natarajan R. High glucose-induced expression of proinflammatory cytokine and chemokine genes in monocytic cells. Diabetes 2003: 52: 1256-1264.
69. Hofmann MA, Schiekofer S, Kanitz M et al. Insufficient glycemic control increases nuclear factor-kappa B binding activity in peripheral blood mononuclear cells isolated from patients with type 1 diabetes. Diabetes Care 1998: 21: 1310-1316.
70. Miao F, Gonzalo IG, Lanting L, Natarajan R. In vivo chromatin remodeling events leading to inflammatory gene transcription under diabetic conditions. J Biol Chem 2004: 279: 18091-18097.
71. Miao F, Smith DD, Zhang L, Min A, Feng W, Natarajan R. Lymphocytes from patients with type 1 diabetes display a distinct profile of chromatin histone H3 lysine 9 dimethylation: an epigenetic study in diabetes. Diabetes 2008: 57: 3189-3198.
72. Villeneuve LM, Reddy MA, Lanting LL, Wang M, Meng L, Natarajan R. Epigenetic histone H3 lysine 9 methylation in metabolic memory and inflammatory phenotype of vascular smooth muscle cells in diabetes. Proc Natl Acad Sci USA 2008: 105: 9047-9052.
73. Reddy MA, Villeneuve LM, Wang M, Lanting L, Natarajan R. Role of the lysine-specific demethylase 1 in the proinflammatory phenotype of vascular smooth muscle cells of diabetic mice. Circ Res 2008: 103: 615-623.
74. Brasacchio D, Okabe J, Tikellis C et al. Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail. Diabetes 2009: 58: 1229-1236.
75. Wilson JR, Jing C, Walker PA et al. Crystal structure and functional analysis of the histone methyltransferase SET7/9. Cell 2002: 111: 105-115.
76. Nishioka K, Chuikov S, Sarma K et al. Set9, a novel histone H3 methyltransferase that facilitates transcription by precluding histone tail modifications required for heterochromatin formation. Genes Dev 2002: 16: 479-489.
77. Dhayalan A, Kudithipudi S, Rathert P, Jeltsch A. Specificity analysis-based identification of new methylation targets of the SET7/9 protein lysine methyltransferase. Chem Biol 2011: 18: 111-120.
78. Okabe J, Orlowski C, Balcerczyk A et al. Distinguishing hyperglycemic changes by Set7 in vascular endothelial cells. Circ Res 2012: 110: 1067-1076.
79. Deering TG, Ogihara T, Trace AP, Maier B, Mirmira RG. Methyltransferase Set7/9 maintains transcription and euchromatin structure at islet-enriched genes. Diabetes 2009: 58: 185-193.
80. Sun G, Reddy MA, Yuan H, Lanting L, Kato M, Natarajan R. Epigenetic histone methylation modulates fibrotic gene expression. J Am Soc Nephrol 2010: 21: 2069-2080.
81. Keating ST, El-Osta A. Chromatin modifications associated with diabetes. J Cardiovasc Transl Res 2012: 5: 399-412.
82. Yang J, Huang J, Dasgupta M et al. Reversible methylation of promoter-bound STAT3 by histone-modifying enzymes. Proc Natl Acad Sci USA 2010: 107: 21499-21504.
83. Berthier CC, Zhang H, Schin M et al. Enhanced expression of Janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy. Diabetes 2009: 58: 469-477.
84. Tuttle HA, Davis-Gorman G, Goldman S, Copeland JG, McDonagh PF. Proinflammatory cytokines are increased in type 2 diabetic women with cardiovascular disease. J Diabetes Complicat 2004: 18: 343-351.
85. Zhong Q, Kowluru RA. Epigenetic changes in mitochondrial superoxide dismutase in the retina and the development of diabetic retinopathy. Diabetes: 60: 1304-1313.
86. Tateishi K, Okada Y, Kallin EM, Zhang Y. Role of Jhdm2a in regulating metabolic gene expression and obesity resistance. Nature 2009: 458: 757-761.
87. Fuks F, Hurd PJ, Wolf D, Nan X, Bird AP, Kouzarides T. The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation. J Biol Chem 2003: 278: 4035-4040.
88. Meehan RR, Lewis JD, Bird AP. Characterization of MeCP2, a vertebrate DNA binding protein with affinity for methylated DNA. Nucleic Acids Res 1992: 20: 5085-5092.
89. Zhang Y, Ng HH, Erdjument-Bromage H, Tempst P, Bird A, Reinberg D. Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes Dev 1999: 13: 1924-1935.
90. Iguchi-Ariga SM, Schaffner W. CpG methylation of the cAMP-responsive enhancer/promoter sequence TGACGTCA abolishes specific factor binding as well as transcriptional activation. Genes Dev 1989: 3: 612-619.
91. Jurkowska RZ, Jurkowski TP, Jeltsch A. Structure and function of mammalian DNA methyltransferases. Chembiochem 2011: 12: 206-222.
92. Maier S, Olek A. Diabetes: a candidate disease for efficient DNA methylation profiling. J Nutr 2002: 132: 2440S-2443S.
93. Reik W, Dean W, Walter J. Epigenetic reprogramming in mammalian development. Science 2001: 293: 1089-1093.
94. Whincup PH, Kaye SJ, Owen CG et al. Birth weight and risk of type 2 diabetes: a systematic review. JAMA 2008: 300: 2886-2897.
95. Kajantie E, Osmond C, Barker DJ, Eriksson JG. Preterm birth-a risk factor for type 2 diabetes? The Helsinki birth cohort study. Diabetes Care 2010: 33: 2623-2625.
96. Park JH, Stoffers DA, Nicholls RD, Simmons RA. Development of type 2 diabetes following intrauterine growth retardation in rats is associated with progressive epigenetic silencing of Pdx1. J Clin Invest 2008: 118: 2316-2324.
97. Holland AM, Gonez LJ, Naselli G, Macdonald RJ, Harrison LC. Conditional expression demonstrates the role of the homeodomain transcription factor Pdx1 in maintenance and regeneration of beta-cells in the adult pancreas. Diabetes 2005: 54: 2586-2595.
98. Hui H, Perfetti R. Pancreas duodenum homeobox-1 regulates pancreas development during embryogenesis and islet cell function in adulthood. Eur J Endocrinol 2002: 146: 129-141.
99. Brissova M, Blaha M, Spear C et al. Reduced PDX-1 expression impairs islet response to insulin resistance and worsens glucose homeostasis. Am J Physiol Endocrinol Metab 2005: 288: E707-714.
100. Kulkarni RN, Jhala US, Winnay JN, Krajewski S, Montminy M, Kahn CR. PDX-1 haploinsufficiency limits the compensatory islet hyperplasia that occurs in response to insulin resistance. J Clin Invest 2004: 114: 828-836.
101. Stoffers DA, Zinkin NT, Stanojevic V, Clarke WL, Habener JF. Pancreatic agenesis attributable to a single nucleotide deletion in the human IPF1 gene coding sequence. Nat Genet 1997: 15: 106-110.
102. Kuroda A, Rauch TA, Todorov I et al. Insulin gene expression is regulated by DNA methylation. PLoS One 2009: 4: e6953.
103. Fu Q, Yu X, Callaway CW, Lane RH, McKnight RA. Epigenetics: intrauterine growth retardation (IUGR) modifies the histone code along the rat hepatic IGF-1 gene. FASEB J 2009: 23: 2438-2449.
104. Ke X, Schober ME, McKnight RA et al. Intrauterine growth retardation affects expression and epigenetic characteristics of the rat hippocampal glucocorticoid receptor gene. Physiol Genomics 2010: 42: 177-189.
105. Heijmans BT, Tobi EW, Stein AD et al. Persistent epigenetic differences associated with prenatal exposure to famine in humans. Proc Natl Acad Sci USA 2008: 105: 17046-17049.
106. Li Y, He Y, Qi L et al. Exposure to the Chinese famine in early life and the risk of hyperglycemia and type 2 diabetes in adulthood. Diabetes 2010: 59: 2400-2406.
107. Tobi EW, Lumey LH, Talens RP et al. DNA methylation differences after exposure to prenatal famine are common and timing- and sex-specific. Hum Mol Genet 2009: 18: 4046-4053.
108. El-Osta A. Glycemic memory. Current opinion in lipidology 2012: 23: 24-29.
109. Jiang M, Zhang Y, Liu M et al. Hypermethylation of hepatic glucokinase and L-type pyruvate kinase promoters in high-fat diet-induced obese rats. Endocrinology 2011: 152: 1284-1289.
110. El-Osta A. Redox mediating epigenetic changes confer metabolic memories. Circ Res 2012: 111: 262-264.
111. Ling C, Del Guerra S, Lupi R et al. Epigenetic regulation of PPARGC1A in human type 2 diabetic islets and effect on insulin secretion. Diabetologia 2008: 51: 615-622.
112. Barres R, Osler ME, Yan J et al. Non-CpG methylation of the PGC-1alpha promoter through DNMT3B controls mitochondrial density. Cell Metab 2009: 10: 189-198.
113. Ek J, Andersen G, Urhammer SA et al. Mutation analysis of peroxisome proliferator-activated receptor-gamma coactivator-1 (PGC-1) and relationships of identified amino acid polymorphisms to type II diabetes mellitus. Diabetologia 2001: 44: 2220-2226.
114. Stenvinkel P, Karimi M, Johansson S et al. Impact of inflammation on epigenetic DNA methylation - a novel risk factor for cardiovascular disease? J Intern Med 2007: 261: 488-499.
115. Kim M, Long TI, Arakawa K, Wang R, Yu MC, Laird PW. DNA methylation as a biomarker for cardiovascular disease risk. PLoS One 2010: 5: e9692.
116. Hiltunen MO, Turunen MP, Hakkinen TP et al. DNA hypomethylation and methyltransferase expression in atherosclerotic lesions. Vasc Med 2002: 7: 5-11.
117. Hiltunen MO, Yla-Herttuala S. DNA methylation, smooth muscle cells, and atherogenesis. Arterioscler Thromb Vasc Biol 2003: 23: 1750-1753.
118. Chan Y, Fish JE, D́Abreo C et al. The cell-specific expression of endothelial nitric-oxide synthase: a role for DNA methylation. J Biol Chem 2004: 279: 35087-35100.
119. Laukkanen MO, Mannermaa S, Hiltunen MO et al. Local hypomethylation in atherosclerosis found in rabbit ec-sod gene. Arterioscler Thromb Vasc Biol 1999: 19: 2171-2178.
120. Sapienza C, Lee J, Powell J et al. DNA methylation profiling identifies epigenetic differences between diabetes patients with ESRD and diabetes patients without nephropathy. Epigenetics 2011: 6: 20-28.
121. Bell CG, Teschendorff AE, Rakyan VK, Maxwell AP, Beck S, Savage DA. Genome-wide DNA methylation analysis for diabetic nephropathy in type 1 diabetes mellitus. BMC Med Genomics 2010: 3: 33.
122. Tregouet DA, Groop PH, McGinn S et al. G/T substitution in intron 1 of the UNC13B gene is associated with increased risk of nephropathy in patients with type 1 diabetes. Diabetes 2008: 57: 2843-2850.
123. Fradin D, Bougneres P. T2DM: Why Epigenetics? J Nutr Metab 2011: 2011: 647514.
124. Madsen-Bouterse SA, Mohammad G, Kanwar M, Kowluru RA. Role of mitochondrial DNA damage in the development of diabetic retinopathy, and the metabolic memory phenomenon associated with its progression. Antioxid Redox Signal 2010: 13: 797-805.
125. Tewari S, Santos JM, Kowluru RA. Damaged mitochondrial DNA replication system and the development of diabetic retinopathy. Antioxid Redox Signal 2012: 17: 492-504.
126. Tewari S, Zhong Q, Santos JM, Kowluru RA. Mitochondria DNA replication and DNA methylation in the metabolic memory associated with continued progression of diabetic retinopathy. Invest Ophthalmol Vis Sci 2012: 53: 4881-4888.
127. Hawkins RD, Hon GC, Ren B. Next-generation genomics: an integrative approach. Nat Rev Genet 2010: 11: 476-486.
128. Rando OJ. Combinatorial complexity in chromatin structure and function: revisiting the histone code. Curr Opin Genet Dev 2012: 22: 148-155.
129. Poy MN, Eliasson L, Krutzfeldt J et al. A pancreatic islet-specific microRNA regulates insulin secretion. Nature 2004: 432: 226-230.
130. Poy MN, Spranger M, Stoffel M. microRNAs and the regulation of glucose and lipid metabolism. Diabetes Obes Metab 2007: 9 (Suppl 2): 67-73.
131. Kato M, Putta S, Wang M et al. TGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat Cell Biol 2009: 11: 881-889.
132. Wang Q, Wang Y, Minto AW et al. MicroRNA-377 is up-regulated and can lead to increased fibronectin production in diabetic nephropathy. FASEB J 2008: 22: 4126-4135.